|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| Found 216 studies with search of: | "Emtricitabine" [TREATMENT] AND HIV [CONDITION] |
| Rank | Status | Study | ||||
|---|---|---|---|---|---|---|
| 1 | Active, not recruiting |
Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 Versus Efavirenz/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults
|
||||
| 2 | Recruiting |
Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen in HIV 1 Infected, Antiretroviral Treatment-Naive Adults
|
||||
| 3 | Active, not recruiting |
Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9350-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults
|
||||
| 4 | Active, not recruiting |
Study of the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 (QUAD) Versus Atripla(R) in HIV Infected, Antiretroviral Treatment-Naive Adults
|
||||
| 5 | Recruiting |
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
|
||||
| 6 | Recruiting |
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
|
||||
| 7 | Withdrawn |
Raltegravir Activity In Lymphoid Tissues
|
||||
| 8 | Completed |
An Open-Label Study of Emtricitabine in Combination With Other Antiretroviral Agents in HIV Infected Pediatric Subjects
|
||||
| 9 | Active, not recruiting |
Study to Evaluate the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults
|
||||
| 10 | Completed |
ALTAIR - Alternative Antiretroviral Strategies : a Comparison of Three Initial Regimens
|
||||
| 11 | Recruiting |
Evaluation of Three Strategies of Second-line Antiretroviral Treatment in Africa (Dakar - Bobo-Dioulasso - Yaoundé)
|
||||
| 12 | Active, not recruiting |
Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults.
|
||||
| 13 | Completed |
PK of Tenofovir, Emtricitabine and Efavirenz in Healthy Volunteers
|
||||
| 14 | Active, not recruiting |
Efficacy of Treatment Intensification With Maraviroc on HIV-1 Viral Latency in Recently Infected Hiv-1 naïve Patients Starting Raltegravir Plus Tenofovir/Emtricitabine
|
||||
| 15 |
Completed
Has Results |
Abacavir/Lamivudine Versus Emtricitabine/Tenofovir Both In Combination With Lopinavir/Ritonavir For The Treatment Of HIV
|
||||
| 16 | Not yet recruiting |
Evaluating the Safety and Tolerability of Antiretroviral Drug Regimens Used as Pre-Exposure Prophylaxis to Prevent HIV Infection in Men Who Have Sex With Men
|
||||
| 17 | Completed |
Tenofovir DF (Disoproxil Fumarate) in Combination With Emtricitabine in HIV-1 Patients
|
||||
| 18 | Recruiting |
Treatment of Acute HIV With Emtricitabine, Tenofovir and Efavirenz (CID 0805)
|
||||
| 19 | Active, not recruiting |
Study to Evaluate Switching From Regimens Consisting of Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed Dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF
|
||||
| 20 | Unknown † |
Raltegravir Switch for Toxicity or Adverse Events
|
|
Previous Page | Studies Shown (1-20) | Next Page (21-40) |
|